Abstract 15586: Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial

Gilles R. Dagenais,Mark Lakshmanan,Leanne Dyal,Charles Atisso,Helen Colhoun,Lars E Ryden,Hertzel C. Gerstein

Abstract 15586: Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial

2020

Gilles R. Dagenais
Mark Lakshmanan
Leanne Dyal
Charles Atisso
Helen Colhoun
Lars E Ryden
Hertzel C. Gerstein

Introduction: In the REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial, weekly subcutaneous dulaglutide 1.5 mg, a glucagon-like peptide-1 receptor agonist, compare...

Keywords:

Intensive care medicine
Type 2 diabetes
Dulaglutide
Post-hoc analysis
cardiovascular risk factors
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations